A Clinical Study of the CardiAQ™ TMVI System (Transapical DS)
A Clinical Study of the CardiAQ™ Transcatheter Mitral Valve Implantation (TMVI) System (Transapical Delivery System)
Sponsor: Edwards Lifesciences
Terminated
Edwards acquired CardiAQ and opted to terminate this study. 2 patients were enrolled and follow-up is complete. No further enrollment or follow-up will occur.
Other terminated trials from Edwards Lifesciences
Other Cardiovascular Disease trials with similar outcome
Listed as NCT02478008, this NA trial focuses on Cardiovascular Disease and Heart Disease and remains terminated or withdrawn. Sponsored by Edwards Lifesciences, it has been updated 9 times since 2015, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Dec 2021 — Jul 2024 [monthly]
Terminated NA
-
Jan 2021 — Dec 2021 [monthly]
Terminated NA
-
Nov 2020 — Jan 2021 [monthly]
Terminated NA
▶ Show 4 earlier versions
-
Jun 2018 — Nov 2020 [monthly]
Terminated NA
-
May 2018 — Jun 2018 [monthly]
Terminated NA
-
Aug 2017 — May 2018 [monthly]
Terminated NA
-
Jan 2017 — Aug 2017 [monthly]
Terminated NA
First recorded
Jun 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Edwards Lifesciences
For direct contact, visit the study record on ClinicalTrials.gov .